Body weight was measured throughout the study
This protects the peptide from rapid clearance and extends its half-life
The REWIND cardiovascular outcome trial also revealed that dulaglutide administration resulted in inferior ocular outcomes, leading to an increased need for interventions such as photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, or vitrectomy compared to placebo recipients [38]
Neurodegenerative Disorders These natural processes can be further enhanced in neurodegenerative disorders , like Alzheimers Disease (AD), Parkinson Disease (PD), Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) or Huntingtons disease (HD), where breakdown of the BBB has been observed
Mioduchoski, FNP-BC Not necessarily